Growth hormone response to baclofen in patients with seasonal affective disorder: Effects of light therapy

Psychoneuroendocrinology

Volumn 24, Issue 2, 1999, Pages 143-153

  Shiah, I Shin ^a,b   A Robertson, Heather ^a   W Lam, Raymond ^a   N Yatham, Lakshmi ^a   M Tam, Edwin ^a   P Zis, Athanasios ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Baclofen; GABA; GABA(B) receptor; Growth hormone; Light therapy; Seasonal affective disorder; Winter depression

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; GROWTH HORMONE;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; GROWTH HORMONE RELEASE; HUMAN; MALE; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRIORITY JOURNAL; PROVOCATION;

ADULT; BACLOFEN; FEMALE; GABA AGONISTS; HUMAN GROWTH HORMONE; HUMANS; KINETICS; MALE; PHOTOTHERAPY; RECEPTORS, GABA-B; SEASONAL AFFECTIVE DISORDER;

EID: 0032980414     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(98)00066-3     Document Type: Article

References (56)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, IV American Psychiatric Association, Washington, DC.
2. Allen J. M., Lam R. W., Remick R. A., Sadovnick A. D. Depressive symptoms and family history in seasonal and nonseasonal mood disorders. American Journal of Psychiatry. 150:1993;443-448.
3. A/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims. Brain Research. 460:1988;114-123.
4. B receptors consistent findings following chronic antidepressant administration? European Journal of Pharmacology. 141:1987;159-162.
5. 2 binding site changes. British Journal of Pharmacology. 93:1988;331-336.
6. Davis L. L., Trivedi M., Kramer G. L., Rush A. J., Orsulak P. J., Akers L., Petty F. Growth hormone response to baclofen: a comparison of 10-mg and 20-mg doses in healthy men. Psychiatry Research. 60:1996;41-47.
7. B agonist baclofen in major depressive disorder. Psychoneuroendocrinology. 22:1997;129-140.
8. Engelbrecht A. H., Russell V. A., Taljaard J. J. F. Lack of effect of bilateral locus coeruleus lesion and antidepressant treatment of gamma-aminobutyric acid receptors in the rat frontal cortex. Neurochemical Research. 9:1994;1119-1123.
9. Gamse R., Vaccaro D. E., Gamse G., Dipace M., Fox T. O., Leeman S. E. Release of immunoreactive somatostatin from hypothalamic cell culture: Inhibition by γ-aminobutyric acid. Proceedings of the National Academy Sciences USA. 77:1980;5552-5556.
10. Gerner R. H., Hare T. A. CSF GABA in normal subjects and patients with depression, schizophrenia, mania and anorexia nervosa. American Journal of Psychiatry. 138:1981;1098-1101.
11. Gerner R. H., Fairbanks L., Anderson G. M., Young J. G., Scheinin M., Linnoila M., Hare T. A., Shaywitz B. A., Cohen D. J. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. American Journal of Psychiatry. 141:1984;1533-1540.
12. Gold B. I., Bower M. B., Roth R. H., Sweeney D. W. GABA levels in CSF of patients with psychiatric disorders. American Journal of Psychiatry. 137:1980;362-364.
13. B receptor function in mouse frontal cortex after repeated administration of antidepressant drugs or electroconvulsive shocks. British Journal of Pharmacology. 92:1987;357-362.
14. Green A. R., Nutt D. J. Antidepressants. Grahame-Smith D. G., Cowen P.J. Psychopharmacology I, Part I: Preclinical Psychopharmacology. 1983;Excerpta Mediea, Amsterdam.
15. Jacobsen F. M., Sack D. A., Wehr T. A., Rogers S., Rosenthal N. E. Neuroendocrine response to 5-hydroxytryptophan in seasonal affective disorder. Archives of General Psychiatry. 44:1987;1086-1091.
16. Joffe R. T., Post R. M., Rubinow D. R., Berrettini W. H., Hare T. A., Ballenger J. C., Roy-Byrne P. P. Cerebrospinal fluid GABA in manic-depressive illness. Bartholini G., Lloyd K. G., Morselli P. L. GABA and Mood Disorders: Experimental and Clinical Research. 1986;187-193 Raven Press, New York.
17. Kaiya H., Namba M., Yoshida H., Nakamura S. Plasma glutamate decarboxylase activity in neuropsychiatry. Psychiatry Research. 6:1982;335-343.
18. Kasa K., Otsuki S., Yamamoto M., Sato M., Kuroda H., Ogawa N. Cerebrospinal fluid γ-aminobutyric acid and homovanillic acid in depressive disorders. Biological Psychiatry. 17:1982;877-883.
19. Koulu M., Lammintausta R., Dahlstrom S. Stimulatory effect of acute baclofen administration on human growth hormone and prolactin secretion in man. Journal of Clinical and Endocrinology and Metabolism. 48:1979;1038-1040.
20. Lam R. W., Gorman C. P., Michalon M., Steiner M., Levitt A. J., Corral M. R., Watson G. D., Morehouse R. L., Tam W., Joffe R. T. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. American Journal of Psychiatry. 152:1995;1765-1770.
21. Leonard B. E. Effect of Antidepressants on Specific Neurotransmitters: Are Such effects Relevant to the Therapeutic Action? den Boer J. A., Sitsen J. M. Handbook of Depression and Anxiety: A Biological Approach. 1994;379-404 Marcel Dekker, New York.
22. Lloyd K. G., Thuret F., Pilc A. Upregulation of γ-aminobutyric acid (GABA)B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. Journal of Pharmacology and Experimental Therapeutics. 235:1985;191-199.
23. Lloyd K. G, Pichat P. GABA Synapses, Depression and Antidepressant Drugs. Dahl S. G., Gram S. M. P., Potter W. Z. Clinical Pharmacology in Psychiatry. 1987;113-126 Springer, Berlin.
24. Lucey J. V., Butcher G., O'Flynn K., Clare A. W., Dinan G. The growth hormone response to baclofen in obsessive compulsive disorder - does the GABA-B receptor mediate obsessive anxiety? Pharmacopsychiatry. 27:1994;23-26.
25. Marchesi C., Chiodera P., De Ferri A., De Risio C., Dasso L., Menozzi P., Volpi R., Coiro V. Reduction of GH response to the GABA-B agonist baclofen in patients with major depression. Psychoneuroendocrinology. 16:1991;475-479.
26. B and β-adrenergic receptors in rat cerebral cortex. Biochemical Pharmacology. 42:1991;1525-1528.
27. Monteleone P., Maj M., Iovino M., Steardo L. GABA, depression and the mechanism of action of antidepressant drugs: a neuroendocrine approach. Journal of Affective Disorders. 20:1990;1-5.
28. Monteleone P., Steardo L., Tanzillo C., Maj M. Chronic antidepressant drug treatment dose not affect GH response to baclofen in depressed subjects. Journal of Neural Transmission. 82:1990;147-152.
29. Muller E. E. Neural control of somatotropic function. Physiology Review. 67:1987;962-1053.
30. O'Flynn K., Dinan T. G. Baclofen-induced growth hormone release in major depression: relationship to dexamethasone suppression test result. American Journal of Psychiatry. 150:1993;1728-1730.
31. Perry E. K., Gibson P. H., Blesses G., Perry R. H., Tomlinson B. E. Neurotransmitter abnormalities in senile dementia. Journal of Neurological Sciences. 34:1977;247-265.
32. Petty F., Schlesser M. A. Plasma GABA in affective illness: a preliminary investigation. Journal of Affective Disorders. 3:1981;339-343.
33. Petty F., Sherman A. D. Plasma GABA levels in psychiatric illness. Journal of Affective Disorders. 6:1984;131-138.
34. Petty F., Kramer G. L., Gullion C. H., Rush A. J. Low plasma γ-aminobutyric acid levels in male patients with depression. Biological Psychiatry. 32:1992;354-363.
35. Petty F. Plasma concentrations of γ-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease? Clinical Chemistry. 40:1994;296-302.
36. Post R. M., Ballenger J. C., Hare T. A., Goodwin F. K., Lake C. R., Jimerson D. C., Bunnery W. E. CSF GABA in normals and patients with affective disorder. Brain Research Bulletin. 5(Supplement 2):1980;755-759.
37. B receptor binding sites in rat frontal cortex. British Journal of Pharmacology. 110:1993;724-735.
38. Rode A, Bidzinski A., Puzynski S. GABA levels in the plasma of patients with endogenous depression and during the treatment with thymoleptics. Psychiatry Polish. 25:1991;4-7.
39. Rosen L. N., Targum S. D., Terman M., Bryant M. J., Hoffman H., Kasper S. F., Hamovit J. R., Docherty J. P., Welch B., Rosenthal N. E. Prevalence of seasonal affective disorder at four latitudes. Psychiatry Research. 31:1990;131-144.
40. Rosenthal N. E., Sack D. A., Gillin J. C., Lewy A. J., Goodwin F. K., Davenport Y., Mueller P. S., Newsome D. A., Wehr T. A. Seasonal affective disorder: a description of syndrome and preliminary findings with light treatment. Archives of General Psychiatry. 41:1984;72-80.
41. Roy A., Dejong J., Ferraro T. CSF GABA in depressed patients and normal controls. Psychological Medicine. 21:1991;613-618.
42. Schwartz P. J., Murphy D. L., Wehr T. A., Garcia-Borreguero D., Oren D. A., Moul D. E., Ozaki N., Snelbaker A. J., Rosenthal N. E. Effects of meta-chlorophenylpiperazine infusions in patients with seasonal affective disorder and healthy control subjects. Archives of General Psychiatry. 54:1997;375-385.
43. Shiah I.-S., Yatham L. N., Lam R. W., Zis A. P. Divalproex sodium attenuates growth hormone response to baclofen in healthy human males. Neuropsychopharmacology. 18:1998;370-376.
44. Shiah I.-S., Yatham L. N. GABA function in mood disorders: an update and critical review. Life Sciences. 63:1998;1289-1303.
45. Spitzer, R. L., Williams, J. B. W., Gibbon, M. and First, M. B., 1990. Structured Clinical Interview for DSM-III-R, Patient Edition. American Psychiatric Association, Washington, DC.
46. Spitzer, R. L., Williams, J. B. W., Gibbon, M. and First, M. B., 1992. Structured Clinical Interview for DSM-III-R, Nonpatient Edition. American Psychiatric Association, Washington, DC.
47. B receptors. Journal of Pharmacology and Experimental Therapeutics. 243:1987;155-159.
48. Tam E. M., Lam R. W., Robertson H. A., Stewart J. N., Yatham L. N., Zis A. P. Atypical depressive symptoms in seasonal and non-seasonal mood disorders. Journal of Affective Disorders. 44:1997;39-44.
49. Terman M, Terman J. S., Quitkin F. M., McGrath P. J., Stewart J. W., Rafferty B. Light therapy for seasonal affective disorder: a review of efficacy. Neuropsychopharmacology. 2:1989;1-22.
50. Thompson P. A., Maes M., Meltzer H. Y. Effects of the placebo control condition in neuroendocrine challenge studies. Psychiatry Research. 52:1994;317-326.
51. Vance M. L., Kaiser F. L., Evans W. S., Thorner M. O., Furlanetto R., Rivier J., Vale W., Perisutti G., Frohman L. A. Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man. Journal of Clinical Endocrinology and Metabolism. 60:1985;370-375.
52. Wesson V. A., Levitt A. J. Light therapy for seasonal affective disorder. Lam R.W. Seasonal Affective Disorder and Beyond: Light Treatment for SAD and non-SAD Conditions. 1998;45-89 American Psychiatric Association, Washington, DC.
53. Williams, J. B. W., Link, M. and Rosenthal, N. E., 1991. Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorders Version (SIGH-SAD). New York Psychiatric Institute, New York.
54. Yatham L. N., Lam R. W., Zis A. P. Growth hormone response to sumatriptan (5HT1D agonist) challenge in seasonal affective disorder: effects of light therapy. Biological Psychiatry. 42:1997;24-29.
55. Young M. J., Bresnitz E. A., Strom B. L. Sample size nomograms for interpreting negative clinical studies. Annals of Internal Medicine. 99:1983;248-251.
56. Zimmer R., Teelken A. W., Meier K. D., Ackenheil M., Zander K. J. Preliminary studies on CSF gamma-aminobutyric acid levels in psychiatric patients before and during treatment with different psychotropic drugs. Progress in Neuropsychopharmacology and Biological Psychiatry. 4:1981;613-620.